Navigation Links
MicroPhage Closes Latest Financing
Date:11/20/2008

LONGMONT, Colo., Nov. 20 /PRNewswire/ -- MicroPhage, Inc., http://www.microphage.com, today announced it has concluded its latest round of financing, which brings total capital raised to $11 million. Investors in this round were a combination of existing and new investors. All funds to date have come from private investors.

MicroPhage will apply proceeds of its financing to complete the validation and launch preparation of their initial diagnostic products, which address the growing need for simple, rapid and highly accurate tests for hospital-acquired infections (HAIs), such as MRSA.

R. Gary Mesch, chairman of MicroPhage commented "MicroPhage investors are confident the company will deliver badly needed diagnostic tools in the fight against MRSA and other HAIs. Closing a significant funding round in this tough financial climate is a noteworthy achievement."

MicroPhage CEO Steve Lundy added: "We have been validating our products in the field and have received excellent feedback from laboratory professionals who tested them against current methods. We are looking forward to completing our validation work and launching products, which leverage the tremendous power of bacteriophage amplification technology for rapid bacterial identification and susceptibility testing."

About MicroPhage

Based in Longmont, Colo. and privately held, MicroPhage, Inc. is working to be a global leader in developing rapid diagnostics products for bacterial identification and antibiotic susceptibility/resistance testing. Using its bacteriophage-based amplification platform, the company has developed a patented process that is a product platform or engine for rapid, easy-to-use, inexpensive diagnostic tests. Its first products, expected in late 2009, will set a new standard for clinicians in MRSA identification and antibiotic susceptibility testing, and are designed to fit the demands of hospitals and laboratories of all sizes. For further information, go to http://www.microphage.com.


'/>"/>
SOURCE MicroPhage, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
2. CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
3. Starfish Ventures Closes Australias Largest Venture Capital Fund With $185 Million Tech Fund
4. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
5. Great Basin Scientific, Inc. Closes $3.9 Million in Equity Funding
6. Micromet Closes $40 Million Private Equity Placement
7. Helix Biopharma Closes $11.4 Million Private Placement
8. ForteBio, Inc. Closes $25 Million In Series C Financing
9. AMDL, Inc. Closes Private Placement of Convertible Notes
10. World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round
11. Pathwork Diagnostics Closes $20M Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
Breaking Biology News(10 mins):